Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.15, delivering a surprise of -15.38%.Over the last four quarters, ...

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.35%. A quarter ago, it was expected that this orthopedic medical device maker would post a loss of $0.03 per share when it actually produced a loss of $0.01, delivering a surprise of 66.67%.Over the last four qu ...

Company Performance - VAREX IMAGING reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and up from $0.16 per share a year ago, representing an earnings surprise of 85.71% [1] - The company posted revenues of $212.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.93%, compared to year-ago revenues of $206.2 million [2] - Over the last four quarters, VAREX IMAGING has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - VAREX IMAGING shares have declined approximately 44% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $207.93 million, and for the current fiscal year, it is $0.54 on revenues of $824.37 million [7] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact VAREX IMAGING's stock performance [5][6]

Rumble Inc. (RUM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.09%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.44, delivering a surprise of -238.46%.Over the last four quarters, the company has not been ab ...

Core Insights - Beauty Health Company (SKIN) reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of 38.46% [1] - The company generated revenues of $69.6 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 10.26%, although this is a decline from $81.4 million in the same quarter last year [2] - Beauty Health shares have declined approximately 10.7% year-to-date, compared to a 4.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $75.25 million, and for the current fiscal year, it is -$0.32 on revenues of $285.58 million [7] - The estimate revisions trend for Beauty Health is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Beauty Health belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Theravance Biopharma reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and compared to a loss of $0.09 per share a year ago, indicating a significant earnings surprise of -54.55% [1] - The company posted revenues of $15.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.20%, but showing an increase from year-ago revenues of $14.5 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Outlook - Theravance Bio shares have increased by approximately 6.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $17.1 million, and for the current fiscal year, it is $0.08 on revenues of $96.9 million [7] - The estimate revisions trend for Theravance Bio is mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Theravance Bio belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Fidus Investment (FDUS) reported quarterly earnings of $0.54 per share, exceeding the Zacks Consensus Estimate of $0.53 per share, but down from $0.59 per share a year ago, indicating a slight earnings surprise of 1.89% [1][2] Financial Performance - The company achieved revenues of $36.5 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.04% and showing an increase from $34.65 million year-over-year [2] - Over the last four quarters, Fidus Investment has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - Fidus Investment shares have declined approximately 10.6% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.53 on revenues of $36.03 million, while for the current fiscal year, the estimate is $2.14 on revenues of $147.18 million [7] - The trend of estimate revisions for Fidus Investment has been favorable leading up to the earnings release [6] Industry Context - The Financial - SBIC & Commercial Industry, to which Fidus Investment belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Fidus Investment may be influenced by the overall outlook for the industry [8]

Company Performance - nLight reported a quarterly loss of $0.04 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.17 per share a year ago, representing an earnings surprise of 77.78% [1] - The company posted revenues of $51.67 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 10.37% and up from $44.53 million in the same quarter last year [2] - Over the last four quarters, nLight has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Outlook - nLight shares have declined approximately 21.9% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $49.67 million, and for the current fiscal year, it is -$0.51 on revenues of $205.63 million [7] Industry Context - The Electronics - Semiconductors industry, to which nLight belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact nLight's stock performance [5]

Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.25%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.42 per share when it actually produced a loss of $0.41, delivering a surprise of 2.38%.Over the last four quarters, the company has su ...

Core Insights - Puma Biotech reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and showing a significant improvement from a loss of $0.05 per share a year ago, resulting in an earnings surprise of 400% [1] - The company achieved revenues of $46 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.65% and increasing from $43.8 million year-over-year [2] Earnings Performance - Over the last four quarters, Puma Biotech has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company had an earnings surprise of 207.14% in the previous quarter, where it reported earnings of $0.43 per share against an expectation of $0.14 per share [1] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $49.38 million, and for the current fiscal year, it is $0.54 on revenues of $216.4 million [7] - The estimate revisions trend for Puma Biotech is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Puma Biotech belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]